Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy. | Front Immunol;13: 940674, 2022. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy.

Salomon, Ran; Dahan, Rony.

Affiliation

Salomon R; Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Dahan R; Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.

Front Immunol ; 13: 940674, 2022.

Article in En | MEDLINE | ID: mdl-35911742

Subject(s)
Key words

CD40; agonistic antibody; bispecific antibodies (BsAbs); cancer immunotherapy; fc receptor; therapeutic antibody

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: CD40 Antigens / Antineoplastic Agents, Immunological / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: CD40 Antigens / Antineoplastic Agents, Immunological / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country: Country of publication: